The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation

European Cytokine Network

Volumn 23, Issue 4, 2012, Pages 140-153

  Reikvam, Håkon ^a   Hatfield, Kimberley Joanne ^a   Fredly, Hanne ^a   Nepstad, Ina ^a   Mosevoll, Knut Anders ^a   Bruserud, Øystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myeloid leukemia; Angiogenesis; Bone marrow; Cytokines; Stem cell transplantation

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTHRACYCLINE; CD135 ANTIGEN; CD31 ANTIGEN; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CYTARABINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRONECTIN RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN TYROSINE KINASE INHIBITOR; RANTES; SCATTER FACTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; APLASTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DRUG MEGADOSE; ENDOTHELIUM CELL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOREGULATION; LEUKEMOGENESIS; MICROANGIOPATHY; MYELODYSPLASTIC SYNDROME; MYOEPITHELIUM CELL; REVIEW; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

ACUTE MYELOID LEUKEMIA; ANGIOGENESIS; BONE MARROW; CYTOKINES; STEM CELL TRANSPLANTATION;

CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOVASCULARIZATION, PATHOLOGIC; REMISSION INDUCTION; STEM CELL TRANSPLANTATION;

EID: 84873718968     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2012.0322     Document Type: Review

References (151)

1. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 89-99.
2. Fredly H, Stapnes Bjornsen C, Gjertsen BT, Bruserud O. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia-a report of five cases. Hematology 2010; 15: 338-43.
3. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New Engl J Med 2008; 358: 1909-18.
4. Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud O. Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications. J Biomed Biotechnol 2011; 2011: 104631.
5. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New Engl J Med 2012 22; 366: 1079-89.
6. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 2005; 5: 229-48.
7. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-74.
8. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. New Engl J Med 2011; 364: 1027-36.
9. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-94.
10. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. New Engl J Med 2003; 349: 743-52.
11. Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007; 21: 453-61.
12. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New Engl J Med 1994; 331: 896-903.
13. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. New Engl J Med 2010; 363: 2091-101.
14. Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118: 6037-42.
15. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-907.
16. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008: 1-11.
17. Stapnes C, Gjertsen BT, Reikvam H, Bruserud O. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Investig Drugs 2009; 18: 433-55.
18. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878-87.
19. Lowenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010; 115: 2586-91.
20. Serve H, Wagner R, Sauerland C, et al. Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial. ASH Annual Meeting Abstracts 2010; 116, Abstract no 333.
21. Jabbour E, Kantarjian H, Ravandi F, et al. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 2011; 117: 1236-44.
22. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25: 226-35.
23. Attar EC, Donohue KA, Amrein PC, et al. Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502. ASH Annual Meeting Abstracts 2010; 116, Abstract no 331.
24. Latagliata R, Bongarzoni V, Carmosino I, et al. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol 2006; 17: 281-5.
25. Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116: 4422-9.
26. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of the angiogenic switch concept. Leukemia 2007; 21: 44-52.
27. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971; 285: 1182-6.
28. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009; 23: 162-9.
29. Madlambayan GJ, Meacham AM, Hosaka K, et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010; 116: 1539-47.
30. Hatfield K, Oyan AM, Ersvaer E, et al. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 2009; 144: 53-68.
31. Hatfield K, Ryningen A, Corbascio M, Bruserud O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer 2006; 119: 2313-21.
32. Shih TT, Hou HA, Liu CY, et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009; 113: 3161-7.
33. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100: 158-73.
34. Rafii S, Shapiro F, Rimarachin J, et al. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood. 1994; 84: 10-9.
35. Schweitzer KM, Drager AM, van der Valk P, et al. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol 1996; 148: 165-75.
36. Ross EA, Freeman S, Zhao Y, et al. A novel role for PECAM-1 (CD31) in regulating haematopoietic progenitor cell compartmentalization between the peripheral blood and bone marrow. PLoS One 2008; 3: e2338.
37. Plett PA, Frankovitz SM, Wolber FM, Abonour R, Orschell-Traycoff CM. Treatment of circulating CD34(+) cells with SDF-1alpha or anti-CXCR4 antibody enhances migration and NOD/SCID repopulating potential. Exp Hematol 2002; 30: 1061-9.
38. Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005; 435: 969-73.
39. Rafii S, Shapiro F, Pettengell R, et al. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood 1995; 86: 3353-63.
40. Mohle R, Moore MA, Nachman RL, Rafii S. Transendothelial migration of CD34+ and mature hematopoietic cells: an in vitro study using a human bone marrow endothelial cell line. Blood 1997; 89: 72-80.
41. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-6.
42. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-21.
43. Rafii S, Mohle R, Shapiro F, Frey BM, Moore MA. Regulation of hematopoiesis by microvascular endothelium. Leuk Lymphoma 1997; 27(5-6): 375-86.
44. Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nature reviews Cancer 2010; 10: 138-46.
45. Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010; 6: 251-64.
46. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012; 481: 457-62.
47. Kobayashi H, Butler JM, O'Donnell R, et al. Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. Nature Cell Bio 2010; 12: 1046-56.
48. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nature Med 2004; 10: 64-71.
49. Hooper AT, Butler JM, Nolan DJ, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 2009; 4: 263-74.
50. Kopp HG, Avecilla ST, Hooper AT, et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood 2005; 106: 505-13.
51. Lo Celso C, Fleming HE, Wu JW, et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 2009; 457: 92-6.
52. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-88.
53. Shen Y, Nilsson SK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol 2012; 19: 250-5.
54. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314: 15-23.
55. Madelung A, Bzorek M, Bondo H, et al. A novel immunohistochemical sequential multi-labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis. Histopathology 2012; 60: 554-60.
56. Zetterberg E, Vannucchi AM, Migliaccio AR, et al. Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica 2007; 92: 597-604.
57. Hamdan R, Zhou Z, Kleinerman ES. SDF-1alpha induces PDGFB expression and the differentiation of bone marrow cells into pericytes. Mol Cancer Res 2011; 9: 1462-70.
58. Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007; 92: 332-41.
59. Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud O. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 2010; 341: 149-72.
60. Olsnes AM, Hatfield KJ, Bruserud O. The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. J BUON 2009; 14 (Suppl 1:): S131-40.
61. Foss B, Ulvestad E, Bruserud O. Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur J Haematol 2001; 66: 365-76.
62. Kessler T, Fehrmann F, Bieker R, Berdel WE, Mesters RM. Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Current Drug Targ 2007; 8: 257-68.
63. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717-21.
64. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923-30.
65. Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 2003; 14: 149-53.
66. Hou HA, Chou WC, Lin LI, et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 2008; 32: 904-12.
67. Naran S, Zhang X, Hughes SJ. Inhibition of HGF/MET as therapy for malignancy. Expert Opin Ther Targets 2009; 13: 569-81.
68. Bruserud O, Tronstad KJ, Berge R. In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum. J Cancer Res Clin Oncol 2005; 131: 377-84.
69. Hatfield KJ, Hovland R, Oyan AM, et al. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008; 22: 287-93.
70. Hjorth-Hansen H, Seidel C, Lamvik J, Borset M, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. Eur J Haematol 1999; 62: 129-34.
71. Kim JG, Sohn SK, Kim DH, et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma 2005; 46: 885-91.
72. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010; 46: 1260-70.
73. Bruserud O, Kittang AO. The chemokine system in experimental and clinical hematology. Curr Top Microbiol Immunol 2010; 341: 3-12.
74. Dimberg A. Chemokines in angiogenesis. Curr Top Microbiol Immunol 2010; 341: 59-80.
75. Reikvam H, Hatfield K, Ersvær E, et al. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status-consequences and potential for pharmacological intervention. Brit J Haemtol 2012; 156: 468-80.
76. Loges S, Heil G, Bruweleit M, et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005; 23: 1109-17.
77. Schliemann C, Bieker R, Padro T, et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006; 91: 1203-11.
78. Schliemann C, Bieker R, Thoennissen N, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 2007; 21: 1901-6.
79. Kümpers P, Koenecke C, Hecker H, et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 2008; 112: 2139-48.
80. Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E, Bruserud O. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opin Investig Drugs 2010; 19: 169-83.
81. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol 2010; 84: 239-51.
82. Hatfield KJ, Reikvam H, Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem 2010; 17: 4448-61.
83. Calandra G, Bridger G, Fricker S. CXCR4 in clinical hematology. Curr Top Microbiol Immunol 2010; 341: 173-91.
84. Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud O. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 2006; 55: 830-40.
85. Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113: 1605-13.
86. Hsu HC, Lee YM, TsaiWH, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002; 63: 64-9.
87. Thomson AW, Lotze MT. The Cytokine Handbook, 4th ed. Academic Press, 2003.
88. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116: 4251-61.
89. Fredly H, ReikvamH, Gjertsen BT, Bruserud O. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol 2012; 87: 368-76.
90. Feng X, Scheinberg P, Wu CO, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011; 96: 602-6.
91. Kersey JH. The role of allogeneic-cell transplantation in leukemia. New Engl J Med 2010; 363: 2158-9.
92. Hubel K, Weingart O, Naumann F, et al. Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. Leuk Lymphoma 2011; 52: 444-57.
93. Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotech 2007; 25: 192-3.
94. Koenecke C, Kumpers P, Lukasz A, et al. Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML. Ann Hematol 2010; 89: 459-67.
95. Melve GK, Ersvssr E, Kittang AO, BruserudO. The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target? Expert Rev Hematol 2011; 4: 563-76.
96. Mielcarek M, Storer B, Martin PJ, et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2012; 119: 2675-8.
97. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-90.
98. Reikvam H, Mosevoll KA, Melve GK, et al. The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biol Blood Marrow Transplant 2012; 18: 190-9.
99. Imado T, Iwasaki T, Kataoka Y, et al. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation. Blood 2004; 104: 1542-9.
100. Kuroiwa T, Kakishita E, Hamano T, et al. Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest 2001; 107: 1365-73.
101. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant 2010; 45: 1-11.
102. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273-8.
103. Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T, Kakishita E. Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant 2001; 28: 197-200.
104. Paczesny S, Levine JE, Braun TM, Ferrara JL. Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant 2009; 15: 33-8.
105. Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008; 112: 1539-42.
106. Uguccioni M, Meliconi R, Nesci S, et al. Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host disease. Blood 1993; 81: 2252-6.
107. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant 1998; 21: 29-32.
108. Akkok CA, Hervig T, Stamnesfet S, et al. Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy 2011; 13: 1259-68.
109. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24.
110. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-darabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004; 10: 3577-85.
111. Zahiragic L, Schliemann C, Bieker R, et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007; 21: 1310-2.
112. Fiedler W, ServeH, Dohner H, et al. Aphase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-93.
113. Fiedler W, Krauter J, Gotze K, et al. A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML. ASH Annual Meeting Abstracts 2010; 116, Abstract no 3285.
114. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27: 3557-65.
115. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009; 18: 189-97.
116. Bruserud O, Hatfield K. Antivascular combo therapy: up-andcoming. Blood 2010; 116: 1389-90.
117. Petit I, Karajannis MA, Vincent L, et al. The microtubule-targeting agentCA4Pregresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 2008; 111: 1951-61.
118. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449-56.
119. Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud O. Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. Crit Rev Oncog 2009; 15(1-2): 1-41.
120. Rushworth SA, MacEwan DJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008; 111: 3793-801.
121. Oyan AM, Anensen N, Hellem Bo T, et al. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer 2009; 9: 77.
122. Olsnes AM, Ersvaer E, Ryningen A, et al. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol 2009; 145: 761-74.
123. Barbarroja N, Aristides-Torres L, Hernandez V, et al. Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leuk Lymphoma 2007; 48: 1187-99.
124. Levine L, Lucci JA, 3rd, Pazdrak B, et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003; 63: 3495-502.
125. Hagemann T, Wilson J, Kulbe H, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005; 175: 1197-205.
126. Tabruyn SP, GriffioenAW. NF-kappa B: a newplayer in angiostatic therapy. Angiogenesis 2008; 11: 101-6.
127. Bruserud O, Reikvam H. Therapeutic targeting of NF-kappaB in myelodysplastic syndromes and acute myeloid leukaemia-the biological heterogeneity. Expert Opin Ther Targets 2010; 14: 1139-42.
128. Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009; 9: 761-76.
129. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004; 6: 507-14.
130. Bruserud O, Hatfield KJ, Reikvam H. Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia-Targeting of disease heterogeneity through direct and indirect antileukemic effects. Leuk Res 2011; 35: 1156-8.
131. Bohonowych JE, Gopal U, Isaacs JS. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol 2010; 2010: 412985.
132. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009; 114: 5034-43.
133. Bruserud O, Hatfield KJ, Reikvam H. Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia-targeting of disease heterogeneity through direct and indirect antileukemic effects. Leuk Res 2011; 35: 1156-8.
134. Hatfield KJ, Bedringsaas SL, Ryningen A, Gjertsen BT, Bruserud O. Hypoxia increases HIF-1alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw 2010; 21: 154-64.
135. Okawa Y, Hideshima T, Steed P, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009; 113: 846-55.
136. Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010; 24: 699-705.
137. Kaufmann SH, Karp JE, Litzow MR, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 2011; 96: 1619-26.
138. Bruserud O, ReikvamH. Heat shock protein 90 (HSP90) inhibition-from experimental to clinical studies. Leuk Res 2010; 34: 1422-3.
139. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102: 19-65.
140. Green AS, Chapuis N, Maciel TT, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010; 116: 4262-73.
141. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
142. Bohm A, Aichberger KJ, Mayerhofer M, et al. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest 2009; 39: 395-405.
143. Reikvam H, Hatfield K, Ersvaer E, Ryningen A, Bruserud Ø. Pharmacological targeting of the PI3K-AKT/PKB-mTOR pathway alters local angioregulation in acute myelogenous leukemia. Haematologica 2010; 95, Abstract no 0634.
144. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. New Engl J Med 2009; 361: 1235-48.
145. Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109: 5129-35.
146. Candal FJ, Rafii S, Parker JT, et al. BMEC-1: a human bone marrow microvascular endothelial cell line with primary cell characteristics. Microvasc Res 1996; 52: 221-34.
147. Gaugler MH, Squiban C, Claraz M, et al. Characterization of the response of human bone marrow endothelial cells to in vitro irradiation. Br J Haematol 1998; 103: 980-9.
148. Mohle R, Salemi P, Moore MA, Rafii S. Expression of interleukin-5 by human bone marrow microvascular endothelial cells: implications for the regulation of eosinophilopoiesis in vivo. Br J Haematol 1997; 99: 732-8.
149. Grosset C, Jazwiec B, Taupin JL, et al. In vitro biosynthesis of leukemia inhibitory factor/human interleukin for DA cells by human endothelial cells: differential regulation by interleukin-1 alpha and glucocorticoids. Blood 1995; 86: 3763-70.
150. Hillyer P, Mordelet E, Flynn G, Male D. Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration. Clin Exp Immunol 2003; 134: 431-41.
151. Schweitzer KM, Vicart P, Delouis C, et al. Characterization of a newly established human bone marrowendothelial cell line: distinct adhesive properties for hematopoietic progenitors compared with human umbilical vein endothelial cells. Lab Invest 1997; 76: 25-36.